INCREASED EXPRESSION OF MUTATED BRCA2 IS ASSOCIATED WITH POOR PROGNOSIS OF PATIENTS WITH HIGH RISK PROSTATE CANCER TREATED WITH DEFINITIVE RADIOTHERAPY

被引：0
|
作者：
Iwamura, Hiromichi
Ito, Jun
Mikami, Jotaro
Ise, Kazue
Kohada, Yuki
Anan, Go
Matsushita, Mabumi
Kaiho, Yasuhiro
Ohyama, Chikara
Nakamura, Yasuhiro
Sato, Makoto
机构：
来源：
JOURNAL OF UROLOGY | 2020年 / 203卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP16-13
引用
下载
收藏
页码：E220 / E220
页数：1
相关论文
共 50 条
  • [31] PSA VALUES AND KINETICS OF BRCA1 AND BRCA2 MUTATION CARRIERS AT HIGH RISK FOR PROSTATE CANCER
    Selkirk, Christina
    Hatcher, David
    Powers, Jacquelyn
    Hulick, Peter
    McGuire, Michael
    Brendler, Charles
    Helfand, Brian T.
    JOURNAL OF UROLOGY, 2014, 191 (04): : E816 - E816
  • [32] Intraductal Carcinoma of the Prostate (IDC-P) is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis
    Risbrigdger, G.
    Taylor, R.
    Sliwinski, A.
    Clouston, D.
    Murphy, D.
    Pederson, J.
    Frydenberg, M.
    Thorne, H.
    Papagiris, M.
    Bolton, D.
    BJU INTERNATIONAL, 2015, 115 : 87 - 87
  • [33] Germline BRCA2 Mutation is not Associated with Increased Tumor-Infiltrating Lymphocytes in Primary Prostate Cancer
    Kaur, Harsimar
    Isaacs, William
    Hicks, Jessica
    De Marzo, Angelo
    Antonarakis, Emmanuel
    Lotan, Tamara
    LABORATORY INVESTIGATION, 2019, 99
  • [34] Low BRCA2 expression predicts poor prognoses in patients with rectal cancer receiving chemoradiotherapy
    Sheu, Ming-Jen
    Chou, Chia-Lin
    Yang, Ching-Chieh
    Lee, Sung-Wei
    Tian, Yu-Feng
    Lin, Chen-Yi
    Hsiao, Sheng-Yen
    Chen, Shang-Hung
    Huang, Wen-Tsung
    PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (05)
  • [35] Germline BRCA2 Mutation is not Associated with Increased Tumor-Infiltrating Lymphocytes in Primary Prostate Cancer
    Kaur, Harsimar
    Isaacs, William
    Hicks, Jessica
    De Marzo, Angelo
    Antonarakis, Emmanuel
    Lotan, Tamara
    MODERN PATHOLOGY, 2019, 32
  • [36] BRCA1 and BRCA2 founder mutations are not associated with a high risk of colorectal cancer.
    Niell, BL
    Rennert, G
    Tomsho, LP
    Bonner, JD
    Gruber, SB
    AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 69 (04) : 253 - 253
  • [37] Increased expression of tumor protein D54 is associated with clinical progression and poor prognosis in patients with prostate cancer
    Ren, Ligang
    Chen, Jing
    Zhang, Xinnan
    ONCOLOGY LETTERS, 2017, 14 (06) : 7739 - 7744
  • [38] BRCA1 and BRCA2 mutation type associated with cancer risk
    Burki, Talha Khan
    LANCET ONCOLOGY, 2015, 16 (05): : E205 - E205
  • [39] BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer
    Cui, Ming
    Gao, Xian-Shu
    Gu, Xiaobin
    Guo, Wei
    Li, Xiaoying
    Ma, Mingwei
    Qin, Shangbin
    Qi, Xin
    Xie, Mu
    Peng, Chuan
    Bai, Yun
    ONCOTARGET, 2017, 8 (25) : 40222 - 40232
  • [40] Increased risk of cervical cancer in high-risk families with and without mutations in the BRCA1 and BRCA2 genes
    Rhiem, K.
    Fischer, C.
    Bosse, K.
    Wappenschmidt, B.
    Schmutzler, R. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345